Oncternal Therapeutics is a clinical-stage oncology company developing first-in-class and novel therapies for both rare and common cancers. Our pipeline has recently expanded and now includes two clinical-stage products with common regulatory and development strategies.
Our cutting-edge scientific approach is focused on targets that are uniquely expressed within cancer cells, resulting in highly targeted new therapies. We also apply a variety of therapeutic strategies to address different medical challenges - from antibodies and antibody-drug conjugates (ADCs) to small molecules and chimeric antigen receptor T-cells (CAR-T).
By leveraging our strong scientific and development skills, as well as academic collaborations, we are working to rapidly advance our two clinical-stage pipeline products, cirmtuzumab and TK216. Both cirmtuzumab and TK216 are being developed for various tumor types, including some of the most devastating and underserved forms of cancer.
|HQ||San Diego, CA, US||Map|
Oncternal Therapeutics total Funding
Oncternal Therapeutics latest funding size
Time since last funding
|4 years ago|
When was Oncternal Therapeutics founded?
Oncternal Therapeutics was founded in 2013.
Who are Oncternal Therapeutics key executives?
Oncternal Therapeutics's key executives are Jim Breitmeyer, Dana McGowan and Langdon Miller.
Who are Oncternal Therapeutics competitors?
Competitors of Oncternal Therapeutics include Aptevo Therapeutics, Aeglea Biotherapeutics and Cleveland BioLabs.
Where is Oncternal Therapeutics headquarters?
Oncternal Therapeutics headquarters is located at 12230 El Camino Real #300, San Diego.
Where are Oncternal Therapeutics offices?
Oncternal Therapeutics has an office in San Diego.
How many offices does Oncternal Therapeutics have?
Oncternal Therapeutics has 1 office.
Receive alerts for 300+ data fields across thousands of companies